Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

percutaneous coronary intervention - anticoagulant - all type of patients

percutaneous coronary intervention - antithrombotics - all type of patients


Related trials

ATOLL, 2010 - enoxaparin vs standard heparin

NAPLES (Tavano), 2009 - bivalirudin vs actionated heparin plus tirofiban

CHAMPION-PCI, 2009 - cangrelor up front vs clopidogrel up front

CHAMPION-PLATFORM, 2009 - cangrelor up front vs delayed clopidogrel

TRA-PCI, 2009 - SCH 530348 vs placebo

HORIZONS-AMI (Stone), 2008 - bivalirudin vs heparin + GP2b3a inhibitors

ISAR-REACT 3, 2008 - bivalirudin vs UFH

Hull, 2006 - extended tinzaparin vs standard treatment

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

Deitcher, 2006 - extended enoxaparin vs standard treatment

ACUITY (Stone) (bivalirudin alone), 2006 - bivalirudin vs heparin + GP2b3a inhibitors

STEEPLE, 2006 - enoxaparin vs UFH

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Chong, 2005 - LMWH at home vs UFH in hospital

JUMBO-TIMI 26, 2005 - prasugrel vs clopidogrel

EVET, 2005 - enoxaparin vs tinzaparin

Wells (subgroup), 2005 - tinzaparin vs dalteparin

REPLACE-1, 2004 - bivalirudin vs UFH

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

THE-PRINCE (Kleber), 2003 - enoxaparin vs UFH

REPLACE-2, 2003 - bivalirudin vs hepatin + anti Gp2b3a

Natarajan (without antiGp2b3a), 2003 - Dalteparin vs UFH

Cesarone, 2003 - extended enoxaparin vs standard treatment

CRUISE, 2003 - Enoxaparin vs UFH

Natarajan (+ antiGp2b3a), 2003 - Dalteparin vs UFH + anti Gp2b3a



See also:

  • All percutaneous coronary intervention clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of Enoxaparin
    		•  

    CRUISE study, 2003

    download pdf: Enoxaparin | antithrombotics for percutaneous coronary intervention

    Treatments

    Studied treatment Enoxaparin 0.75 mg/kg bolus
    Control treatment UFH 60 IU/kg bolus, then titrated to ACT > 200
    Concomittant treatment Eptifibatide, aspirin, clopidogrel

    Patients

    Patients Urgent or elective PCI

    Method and design

    Randomized effectives 129 / 132 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 2,7 +30 days
    Primary endpoint hemoglobin


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Bleeding

    0 / 129
         3 / 132
         classic 0,08 [0,00;4,57]

    MACE

    11 / 129
         10 / 132
         classic 1,13 [0,50;2,56]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Bleeding 0 / 129 (0,4%) 3 / 132 (2,3%) 0,17 [0,01;3,37]
    MACE 11 / 129 (8,5%) 10 / 132 (7,6%) 1,13 [0,50;2,56]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    MACE 8,53% 7,58% 9,5‰

    Meta-analysis of all similar trials:

    anticoagulant in percutaneous coronary intervention for all type of patients

    antithrombotics in percutaneous coronary intervention for all type of patients



    Reference(s)

    Trials register # NA
    • Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.. J Am Coll Cardiol 2003;41:20-5
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend